Amplify Weight Loss Drug & Treatment ETF (THNR)

Assets	$2.95M
Expense Ratio	0.59%
PE Ratio	24.31
Shares Out	130,000
Dividend (ttm)	$0.22
Dividend Yield	0.97%
Ex-Dividend Date	Dec 30, 2024
Payout Ratio	23.51%
1-Year Return	-13.86%

Volume	1,345
Open	22.73
Previous Close	22.66
Day's Range	22.59 - 22.73
52-Week Low	18.56
52-Week High	28.19
Beta	n/a
Holdings	23
Inception Date	May 21, 2024

About THNR

Fund Home Page

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.

• Asset Class: Equity
• Category: Health
• Region: Global
• Stock Exchange: NYSEARCA
• Ticker Symbol: THNR
• ETF Provider: Amplify Investments
• Index Tracked: VettaFi Weight Loss Drug Index

Top 10 Holdings

69.75% of assets

Name	Symbol	Weight
Eli Lilly and Company	LLY	12.85%
Novo Nordisk A/S	NVO	10.94%
Regeneron Pharmaceuticals, Inc.	REGN	7.00%
Chugai Pharmaceutical Co., Ltd.	4519	6.94%
Amgen Inc.	AMGN	6.62%
Pfizer Inc.	PFE	5.15%
Merck & Co., Inc.	MRK	5.13%
AbbVie Inc.	ABBV	5.08%
Roche Holding AG	ROG	5.06%
Gilead Sciences, Inc.	GILD	4.98%

Dividends

Ex-Dividend	Amount	Pay Date
Dec 30, 2024	$0.2199	Dec 31, 2024